This research also unveiled a novel regulatory framework whereby HCC progression is mediated through the TRERNA1/miR-22-3p/NRAS axis, suggesting TRERNA1 as a potential tumor biomarker and therapeutic target (Song et al., 2021). This evidence concerns the gene TRERNA1 and hepatocellular carcinoma.